AT7867 promotes pancreatic progenitor differentiation of human iPSCs and accelerates diabetes reversal

Summary Generation of pure pancreatic progenitor cells (PPs) is critical for clinical translation of stem cell derived islets. Herein, we performed PP differentiation with and without AKT/P70 inhibitor AT7867 and characterized the resulting cells at protein and transcript level in vitro and in vivo upon transplantation into diabetic mice. AT7867 treatment increased the percentage of PDX1 + NKX6.1 + (-AT7867: 50.9% [IQR 48.9%-53.8%]; +AT7867: 90.8% [IQR 88.9%-93.7%]; p=0.0021 ) and PDX1 + GP2 + PP cells (-AT7867: 39.22% [IQR 36.7%-44.1%; +AT7867: 90.0% [IQR 88.2%-93.6%]; p=0.0021 ). Transcriptionally, AT7867 treatment significantly upregulated PDX1 ( p=0.0001 ), NKX6.1 ( p=0.0005 ) and GP2 ( p=0.002 ) expression compared to controls, while off-target markers PODXL ( p<0.0001 ) and TBX2 ( p <0.0001 ) were significantly downregulated. Transplantation of AT7867 treated PPs resulted in faster hyperglycemia reversal in diabetic mice compared to controls (time and group: p<0.0001 ). Overall, our data shows that AT7867 enhances PP cell differentiation leading to accelerated diabetes reversal.